Document is current

Article History

Received: 17 March 2025

Accepted: 9 April 2025

First Online: 9 May 2025

Declarations

:

: The RAPID-HCC trial has received ethical approval from the National Ethics Committees in France: ANSM – Agence de sécurité du médicament et des produits de santé et Comité de protection des personnes Ile de France III (Ethics approval number 2022-A02151 - 42). All participating centers involved in this multi-centre study, have obtained local ethical approvals as required by French regulations. Informed consent will be obtained from all participants prior to their enrollment in the trial. The consent process will include a comprehensive explanation of the study’s purpose, procedures, potential risks, and benefits. Participants will be given opportunity to ask questions and will be informed of their right to withdraw from the study at any time without any consequence to their ongoing medical care This study adheres to the principles outlined in the Declaration of Helsinki and complies with the ethical standards of the institutional and national research committees. The confidentiality and anonymity of all participants will be strictly maintained throughout the study.

: Not applicable—this document does not contain any identifying images or personal or clinical details of participants, nor will such details be included in any future study reports. For access to participant information materials and the informed consent form, please contact the corresponding author.

: The authors declare no competing interests.